REGISTER
NMPA Approves Durvalumab Plus Tremelimumab for First-Line EGFR/ALK-Negative NSCLC
China's NMPA has approved AstraZeneca's durvalumab plus tremelimumab regimen for first-line treatment of driver-gene-negative non-small cell lung cancer, according to the source article's interpretation of the filing. The approval adds an eighth China indication for durvalumab and marks the first domestic approval for tremelimumab.

China's National Medical Products Administration (NMPA) has approved AstraZeneca's durvalumab plus tremelimumab combination for marketing in China. Based on the regimen's overseas approvals and the evidence cited in the source article, the Insight Database inferred that the new indication is first-line treatment for driver-gene-negative NSCLC. The decision adds an eighth China indication for durvalumab and marks the first domestic approval for tremelimumab.

Durvalumab (Imfinzi) is a PD-L1 monoclonal antibody that blocks PD-L1 binding to PD-1 and CD80. The approval was supported by the phase III POSEIDON trial (NCT03164616/CTR20180636), which enrolled 1,186 patients globally, including 175 in mainland China. Compared with chemotherapy alone, the tremelimumab/durvalumab/chemotherapy arm reduced the risk of death by 23% (HR 0.77; 95% CI 0.65-0.92; p=0.00304), with median OS of 14.0 vs 11.7 months and median PFS of 6.2 vs 4.8 months. Five-year follow-up published in 2024 showed sustained OS benefit, with a five-year OS rate of 15.7% versus 6.8% for chemotherapy alone.

The article also cited AstraZeneca's China expansion-cohort update at ELCC 2025, where both the tremelimumab/durvalumab/chemotherapy group and the durvalumab/chemotherapy group showed numerical PFS and OS improvement versus chemotherapy alone. In the cited safety analysis, grade 3/4 treatment-related adverse events occurred in 65.5%, 62.3% and 49.1% of patients in the tremelimumab/durvalumab/chemotherapy, durvalumab/chemotherapy and chemotherapy groups, respectively; treatment-related mortality was 5.2%, 0% and 0%. The article noted that nivolumab plus ipilimumab had been the only previously approved CTLA-4 plus PD-(L)1 dual-immunotherapy regimen in China, and that tremelimumab now becomes the third CTLA-4 monoclonal antibody approved in the country.

Fig. Screenshot from ELCC 2025.

0
0
Loading